Randomised Phase II Trial Data on the Combination of 2nd-line Osimertinib and Bevacizumab Versus Standard of Care Osimertinib in EGFR T790M-mutated Advanced NSCLC

The ESMO Virtual Plenaries are freely available to all healthcare professionals working in Oncology.

Programme

Wednesday, 12 May 2021

18:15-19:15 CEST

Welcome and introduction, Scientific background and context

Pilar Garrido, University Hospital Ramón y Cajal (IRYCIS), Madrid, Spain

A randomized phase II study of second-line osimertinib (Osi) and bevacizumab (Bev) versus Osi in advanced non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) and T790M mutations (mt): Results from the ETOP BOOSTER trial

Ross Soo, National University Hospital, Singapore

Critical analysis and perspectives

Edward Garon, UCLA Hematology/Oncology Santa Monica, Santa Monica, CA, USA

Discussion and Q&A (i)

Faculty and online audience

Thursday, 13 May 2021

12:00-13:00 CEST (18:00 HKT / 19:00 JST / 20:00 AEST)

Webcast of 12 May presentations, Discussion and Q&A (ii)

Faculty and online audience:

Ben Solomon, Peter MacCallum Cancer Center, Melbourne, Australia

Ross Soo, National University Hospital, Singapore

Edward Garon, UCLA Hematology/Oncology Santa Monica, Santa Monica, CA, USA

Tony SK Mok, Prince of Wales Hospital, Hong Kong, China

Hidehito Horinouchi, National Cancer Center - Tsukiji Campus, Tokyo, Japan